Net revenues for Q1 2026 were $33.7 million, a 3.0% decrease from $34.7 million in Q1 2025. Net income reached $1.0 million, compared to a net loss of $0.3 million in the prior year period. Patient Services segment revenue grew 6.4% to $22.1 million, fueled by strong performance in Oncology and Wound Care. Device Solutions segment revenue declined 16.9% to $11.6 million, largely due to a restructured GE Healthcare contract and the impact of a prior-year large customer rental buyout. Gross margin improved to 58.4% from 55.2% in the same period last year. Operating income rose to $1.6 million from $0.6 million in Q1 2025.